Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fluocinolone acetonide
Drug ID BADD_D00924
Description Fluocinolone acetonide, with the formula 6-alpha, 9-alpha-difluoro-16-alpha, 17 alpha-acetonide, is a corticosteroid that presents a high lipophilicity.[T357] It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices.[T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676]
Indications and Usage For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (Retisert).
Marketing Status Prescription; Discontinued
ATC Code C05AA10; D07AC04; S01BA15; S02BA08
DrugBank ID DB00591
KEGG ID D01825
MeSH ID D005446
PubChem ID 6215
TTD Drug ID D02QJH
NDC Product Code 64980-331; 63629-8655; 51927-0150; 68462-185; 0299-5500; 46439-8709; 64980-330; 51672-1365; 10135-670; 43538-911; 70752-159; 68791-101; 24208-416; 65162-704; 53183-0261; 49452-3156; 68462-591; 65162-703; 43538-900; 0168-0064; 71879-136; 65162-702; 43538-920; 71161-134; 0713-0709; 45802-887; 68791-102; 45802-485; 0395-8243; 43386-069; 43538-910; 71428-002; 70752-158; 0713-0223; 76420-163; 45802-009; 43538-921; 39328-079; 70752-156; 43538-901; 51672-1357; 68611-190; 0713-0224; 68791-103; 63629-8656; 51672-1356; 38779-0022; 68462-590
Synonyms Fluocinolone Acetonide | Acetonide, Fluocinolone | Fluortriamcinolone Acetonide | Acetonide, Fluortriamcinolone | Flurosyn | Jellin | Jellisoft | Synalar | Synalar-HP | Synalar HP | Synemol | Synamol | Alvadermo | Capex | Co-Fluocin | Co Fluocin | Cortiespec | Derma-Smooth FS | Derma Smooth FS | Flucinar | Fluocid | Fluodermo | Fluonid | Fluotrex | Flusolgen | Gelidina
Chemical Information
Molecular Formula C24H30F2O6
CAS Registry Number 67-73-2
SMILES CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)CO)C)O)F)C)F)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Retinal detachment12.01.04.004; 06.09.03.0030.002297%
Retinal haemorrhage24.07.05.003; 06.10.01.001--Not Available
Rhinitis11.01.13.004; 22.07.03.006--
Rhinorrhoea22.02.05.010--
Sinusitis22.07.03.007; 11.01.13.005--
Skin atrophy23.01.05.001--
Skin disorder23.03.03.007--Not Available
Skin hyperpigmentation23.05.01.003--
Skin hypopigmentation23.05.02.003--
Skin infection23.09.04.002; 11.01.12.003--
Skin irritation23.03.04.009--Not Available
Skin striae23.01.05.002--Not Available
Swelling08.01.03.0150.001532%Not Available
Telangiectasia24.03.03.003; 23.06.03.001--
Tympanic membrane perforation12.01.14.001; 04.05.04.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.0010.001532%
Vertigo17.02.12.002; 04.04.01.003--
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.0070.001532%
Visual acuity reduced17.17.01.011; 06.02.03.0010.006127%
Visual field defect17.17.01.001; 06.02.07.0030.001532%Not Available
Visual impairment06.02.06.0080.013019%Not Available
Vitreous floaters06.09.01.0050.005361%
Vitreous haemorrhage24.07.05.005; 06.10.03.0010.006127%
Vitreous opacities06.09.01.007--Not Available
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Wound dehiscence12.02.05.003--
Excoriation23.03.11.003; 12.01.06.007--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages